Joaquin Valdes

3.3k total citations · 1 hit paper
31 papers, 2.6k citations indexed

About

Joaquin Valdes is a scholar working on Infectious Diseases, Immunology and Dermatology. According to data from OpenAlex, Joaquin Valdes has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Infectious Diseases, 12 papers in Immunology and 7 papers in Dermatology. Recurrent topics in Joaquin Valdes's work include HIV/AIDS drug development and treatment (11 papers), Psoriasis: Treatment and Pathogenesis (10 papers) and Dermatology and Skin Diseases (7 papers). Joaquin Valdes is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), Psoriasis: Treatment and Pathogenesis (10 papers) and Dermatology and Skin Diseases (7 papers). Joaquin Valdes collaborates with scholars based in United States, Canada and Germany. Joaquin Valdes's co-authors include John M. Leonard, Kim Papp, Ann Hsu, Kenneth B. Gordon, Bruce Strober, Richard G. Langley, Yihua Gu, Charles A. Boucher, Michael S. Saag and David D. Ho and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Joaquin Valdes

31 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

2018 452 citations Kenneth B. Gordon, Bruce Strober et al. The Lancet profile →

Peers

Countries citing papers authored by Joaquin Valdes

Since Specialization

Citations

This map shows the geographic impact of Joaquin Valdes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquin Valdes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquin Valdes more than expected).

Fields of papers citing papers by Joaquin Valdes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquin Valdes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquin Valdes. The network helps show where Joaquin Valdes may publish in the future.

Co-authorship network of co-authors of Joaquin Valdes

This figure shows the co-authorship network connecting the top 25 collaborators of Joaquin Valdes. A scholar is included among the top collaborators of Joaquin Valdes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joaquin Valdes. Joaquin Valdes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Protocol and design of the REPOSE study: a double-blinded, randomised, placebo-controlled trial to evaluate the efficacy of suvorexant to improve postoperative sleep and reduce delirium severity in older patients undergoing non-cardiac surgery 2025 ·BMJ Open ·(unknown), (unknown), Craig A. Peterson, Duy Tran, Sam Wu, Joaquin Valdes, (unknown), (unknown), (unknown), Wissam Mansour, Mary Cooter, Karthik Raghunathan, Miriam M. Treggiari, (unknown), Michael J. Devinney	1
2	Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis 2020 ·JAMA Dermatology ·Matthias Augustin, Jo Lambert, (unknown), Elizabeth H. Thompson, Min Yang, Eric Q. Wu, (unknown), Ziqian Geng, Joaquin Valdes, Avani Joshi, Kenneth B. Gordon	40
3	Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial 2019 ·The Journal of Dermatology ·Mamitaro Ohtsuki, Hideki Fujita, Masao Watanabe, (unknown), Mary Flack, Xin Huang, Susumu Kitamura, Joaquin Valdes, Atsuyuki Igarashi	79
4	Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease 2019 ·Clinical Infectious Diseases ·Edward Gane, Fred Poordad, Neddie Zadeikis, Joaquin Valdes, Chih-Wei Lin, Wei Liu, Armen Asatryan, Stanley Wang, Catherine Stedman, Susan Greenbloom, Tuan Nguyen, Magdy Elkhashab, Marcus‐Alexander Wörns, Albert Tran, (unknown), Carolyn M. Setze, Yao Yu, Edward Tam, Ariel Porcalla, Federico Mensa	23
5	EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS 2018 ·Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez	10
6	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials breakdown → 2018 ·The Lancet ·Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez	452
7	Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial 2017 ·The Lancet Infectious Diseases ·Xavier Forns, Samuel S. Lee, Joaquin Valdes, Sabela Lens, Reem Ghalib, Humberto Aguilar, Franco Felizarta, Tarek Hassanein, Holger Hinrichsen, Diego Rincón, Rosa M. Morillas, Stefan Zeuzem, Yves Horsmans, David R. Nelson, Yao Yu, Preethi Krishnan, Chih‐Wei Lin, Jens Kort, Federico Mensa	234
8	Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis 2017 ·Gastroenterology ·Edward Gane, Fred Poordad, Joaquin Valdes, Chih‐Wei Lin, Wei Liu, Armen Asatryan, Stanley Wang, Catherine Stedman, Susan Greenbloom, Tuan Nguyen, Magdy Elkhashab, Marcus‐Alexander Wörns, Albert Tran, (unknown), Yao Yu, Ariel Porcalla, Federico Mensa	1
9	Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis 2017 ·Journal of Hepatology ·E. Gane, F. Poordad, Joaquin Valdes, (unknown), (unknown), Armen Asatryan, (unknown), Catherine Stedman, Susan Greenbloom, (unknown), (unknown), Marcus‐Alexander Wörns, Albert Tran, (unknown), Yao Yu, Ariel Porcalla, Federico Mensa	3
10	Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis 2012 ·Journal of the European Academy of Dermatology and Venereology ·Richard G. Langley, Kim Papp, Alice B. Gottlieb, Gerald G. Krueger, Kenneth B. Gordon, David A. Williams, Joaquin Valdes, Carolyn M. Setze, Bruce Strober	56
11	A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis 2011 ·New England Journal of Medicine ·Kristian Reich, Richard G. Langley, Kim Papp, Jean‐Paul Ortonne, Kristina Unnebrink, Martin Kaul, Joaquin Valdes	150
12	A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis 2011 ·Journal of Investigative Dermatology ·Kenneth B. Gordon, Richard G. Langley, Alice B. Gottlieb, Kim Papp, Gerald G. Krueger, Bruce Strober, David A. Williams, Yihua Gu, Joaquin Valdes	139
13	A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis 2010 ·Multiple Sclerosis Journal ·Timothy R. Vollmer, Daniel Wynn, (unknown), Joaquin Valdes	50
14	Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study 2004 ·Current Medical Research and Opinion ·Ernie Riffer, (unknown), Robert Palmér, Virginia D. Shortridge, Todd Busman, Joaquin Valdes	13
15	A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection 1995 ·New England Journal of Medicine ·Martin Markowitz, Michael S. Saag, William G. Powderly, Arlene Hurley, Ann Hsu, Joaquin Valdes, David Henry, Fred R. Sattler, (unknown), John M. Leonard, David D. Ho	403
16	A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease 1995 ·New England Journal of Medicine ·Sven A. Danner, Andrew Carr, John M. Leonard, (unknown), Francesc Gudiol, (unknown), (unknown), Rafael Rubio, Emilio Bouza, Vicente Pintado, (unknown), Juan García de Lomas, Rafaël Delgado, Jan C.C. Borleffs, Ann Hsu, Joaquin Valdes, Charles A. Boucher, David A. Cooper	472
17	SAFETY, PHARMACOKINETICS AND VIROLOGICAL/IMMUNOLOGICAL EFFICACY OF ABT-538, A HIV-PROTEASE INHIBITOR. A RANDOMISED, PLACEBO-CONTROLLED PHASE I/II STUDY 1994 ·AIDS ·S. A. Danner, (unknown), Francesc Gudiol, (unknown), Jordi Tor, Rafael Rubio, Joaquin Valdes, John M. Leonard	2
18	The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa 1990 ·Journal of Antimicrobial Chemotherapy ·Joaquin Valdes, Aldona L. Baltch, Raymond P. Smith, Mark C. Hammer, William J. Ritz	14
19	Comparative Therapy with Cefpirome Alone and in Combination with Rifampin and/or Gentamicin against a Disseminated Pseudomonas aeruginosa Infection in Leukopenic Mice 1990 ·The Journal of Infectious Diseases ·Joaquin Valdes, Aldona L. Baltch, R. P. Smith, M. Franke, William J. Ritz, (unknown), Poul Michelsen, Jaswant Singh	8
20	Anti-inflammatory effects of xylopropamine. 1957 ·PubMed ·Randall Lo, (unknown), Joaquin Valdes	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact